A 47-year-old woman presents to her GP with a 14-month history of menstrual periods occurring every 18-35 days with variable flow. Some cycles are heavy lasting 8 days, others are light lasting 3 days. Pelvic examination reveals a normal-sized, mobile uterus. She has no intermenstrual or postcoital bleeding. What is the most appropriate initial investigation?
Q32
A 35-year-old nulliparous woman presents with 7 weeks amenorrhoea and left-sided pelvic pain. Transvaginal ultrasound demonstrates a 35 mm left tubal ectopic pregnancy with fetal cardiac activity visible. Serum beta-hCG is 8,500 IU/L. There is a small amount of free fluid in the pouch of Douglas. She is haemodynamically stable with blood pressure 118/76 mmHg and pulse 78 bpm. She strongly desires future fertility. What is the most appropriate definitive management?
Q33
A 42-year-old woman with heavy menstrual bleeding undergoes endometrial biopsy which shows complex endometrial hyperplasia without atypia. Her BMI is 36 kg/m² and she has type 2 diabetes mellitus. She wishes to preserve her fertility as she is planning conception with her new partner. What is the most appropriate management?
Q34
A 30-year-old woman is found to have a right cornual ectopic pregnancy measuring 18 mm with a serum beta-hCG of 2,400 IU/L. She is haemodynamically stable with mild right lower quadrant pain. There is no haemoperitoneum on ultrasound. She has had two previous lower segment caesarean sections. What is the most appropriate initial management for this patient?
Q35
A 44-year-old woman presents with heavy menstrual bleeding lasting 8 days each cycle for the past 10 months. She has no intermenstrual or postcoital bleeding. Pelvic examination is normal and transvaginal ultrasound shows a uniformly enlarged uterus measuring 11 cm with heterogeneous myometrium and no focal lesions. Endometrial thickness is 9 mm in the secretory phase. Full blood count shows haemoglobin of 102 g/L. She has completed her family and desires definitive treatment. What is the most appropriate next step in management?
Q36
A 27-year-old woman presents to the emergency department with 6 weeks amenorrhoea and mild cramping lower abdominal pain. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 12 mm and no adnexal masses. Serum beta-hCG is 950 IU/L. A repeat beta-hCG test 48 hours later shows a level of 1,280 IU/L. She is haemodynamically stable with mild tenderness in the right iliac fossa. What is the most appropriate classification of this clinical scenario?
Q37
A 40-year-old woman with von Willebrand disease type 1 presents with heavy menstrual bleeding that significantly impacts her quality of life. She reports flooding, passing large clots, and requiring time off work. Previous treatments with tranexamic acid and mefenamic acid provided insufficient improvement. She does not wish to have more children. Pelvic examination and ultrasound are normal. What is the most appropriate next management step?
Q38
A 36-year-old woman with a history of pelvic inflammatory disease presents with 6 weeks amenorrhoea and minimal brown vaginal discharge. She has mild left iliac fossa discomfort but is haemodynamically stable. Transvaginal ultrasound shows an empty uterus and a 28 mm left adnexal mass with a hyperechoic ring. Free fluid is visible in the pouch of Douglas. Serum beta-hCG is 2200 IU/L. She has normal renal and liver function and agrees to medical management. What additional investigation should be performed before administering methotrexate?
Q39
A 48-year-old perimenopausal woman presents with a 13-month history of increasingly irregular and heavy menstrual bleeding. She experiences flooding with clots and cycles varying between 18-45 days. Pelvic examination is normal. Transvaginal ultrasound shows endometrial thickness of 14 mm and normal ovaries. What is the most important next investigation?
Q40
A 43-year-old woman with heavy menstrual bleeding undergoes hysteroscopy which reveals a normal uterine cavity with no polyps or fibroids. Endometrial biopsy shows proliferative endometrium with no atypia. She has regular cycles every 28 days. Full blood count shows haemoglobin 102 g/L. She does not wish to use hormonal treatments. What is the most appropriate pharmacological management?
Gynaecology UK Medical PG Practice Questions and MCQs
Question 31: A 47-year-old woman presents to her GP with a 14-month history of menstrual periods occurring every 18-35 days with variable flow. Some cycles are heavy lasting 8 days, others are light lasting 3 days. Pelvic examination reveals a normal-sized, mobile uterus. She has no intermenstrual or postcoital bleeding. What is the most appropriate initial investigation?
A. Full blood count and serum ferritin
B. Transvaginal ultrasound scan (Correct Answer)
C. Hysteroscopy and endometrial biopsy
D. Serum FSH, LH and oestradiol
E. Thyroid function tests
Explanation: ***Transvaginal ultrasound scan***
- This is the first-line imaging modality to identify structural abnormalities like **endometrial polyps**, **submucosal fibroids**, or thickened endometrium in perimenopausal women with irregular bleeding.
- In women over 45 with changed menstrual patterns, excluding **structural pathology** or malignancy is a priority, even if the physical examination is unremarkable.
*Full blood count and serum ferritin*
- These tests are used to evaluate **iron-deficiency anaemia** resulting from heavy menstrual bleeding but do not diagnose the underlying cause of irregularity.
- While important for supportive care, they are secondary to investigations aimed at identifying **structural or neoplastic causes**.
*Hysteroscopy and endometrial biopsy*
- **Hysteroscopy** is generally reserved as a second-line investigation or when a **transvaginal ultrasound** suggests intracavitary pathology or an abnormal endometrial thickness.
- Endometrial biopsy is specifically indicated for **postmenopausal bleeding** or persistent **intermenstrual bleeding**, which this patient does not currently exhibit.
*Serum FSH, LH and oestradiol*
- These hormones are often used to confirm **perimenopause** or **menopause**, but they are not recommended for routine use in women over 45 to guide management of abnormal bleeding.
- Confirming a hormonal status does not negate the need to rule out **endometrial hyperplasia** or structural lesions in the setting of irregular bleeding.
*Thyroid function tests*
- **Hypothyroidism** or hyperthyroidism can cause menstrual irregularities, but they are rarely the primary cause in a 47-year-old without other systemic symptoms.
- Clinical guidelines prioritize the exclusion of **uterine pathology** over endocrine screening in the perimenopausal age group presenting with variable flow.
Question 32: A 35-year-old nulliparous woman presents with 7 weeks amenorrhoea and left-sided pelvic pain. Transvaginal ultrasound demonstrates a 35 mm left tubal ectopic pregnancy with fetal cardiac activity visible. Serum beta-hCG is 8,500 IU/L. There is a small amount of free fluid in the pouch of Douglas. She is haemodynamically stable with blood pressure 118/76 mmHg and pulse 78 bpm. She strongly desires future fertility. What is the most appropriate definitive management?
A. Expectant management with serial beta-hCG monitoring
B. Single-dose intramuscular methotrexate 50 mg/m²
C. Two-dose intramuscular methotrexate regimen
D. Laparoscopic salpingotomy
E. Laparoscopic salpingectomy (Correct Answer)
Explanation: ***Laparoscopic salpingectomy***- Surgical management is mandated due to the presence of **fetal cardiac activity**, a **mass size of 35 mm**, and a high **beta-hCG of 8,500 IU/L**, all of which contraindicate medical or expectant management.- **Salpingectomy** is the definitive treatment, reducing the risk of **persistent trophoblastic tissue** and recurrent ectopic pregnancy in the affected tube, and is generally preferred for high-risk features even in women desiring future fertility if the contralateral tube is healthy.*Expectant management with serial beta-hCG monitoring*- This approach is suitable only for **clinically stable** patients with small, non-growing ectopic pregnancies, no fetal cardiac activity, and **decreasing beta-hCG levels** (typically <1,000-1,500 IU/L).- The patient's **fetal cardiac activity**, large mass size, and high beta-hCG level indicate a high risk of rupture, making expectant management unsafe.*Single-dose intramuscular methotrexate 50 mg/m²*- Medical management with methotrexate is contraindicated when **fetal cardiac activity** is detected, and its efficacy significantly decreases with **beta-hCG levels >5,000 IU/L**.- The ectopic mass size of 35 mm is also at the upper limit for methotrexate treatment, increasing the risk of failure and subsequent rupture.*Two-dose intramuscular methotrexate regimen*- Although potentially more effective than single-dose for higher beta-hCG, the presence of **fetal cardiac activity** remains a strong contraindication for any methotrexate regimen.- This regimen still carries a significant risk of treatment failure and **tubal rupture** in cases with visible cardiac activity and larger ectopic masses.*Laparoscopic salpingotomy*- While preserving the tube, **salpingotomy** carries a higher risk of **persistent trophoblastic tissue** requiring further intervention, especially with a large mass (35 mm) and **fetal cardiac activity**.- Given the high-risk features, **salpingectomy** offers a more definitive resolution and reduces the risk of complications, making it the safer choice even with the desire for fertility.
Question 33: A 42-year-old woman with heavy menstrual bleeding undergoes endometrial biopsy which shows complex endometrial hyperplasia without atypia. Her BMI is 36 kg/m² and she has type 2 diabetes mellitus. She wishes to preserve her fertility as she is planning conception with her new partner. What is the most appropriate management?
A. Levonorgestrel intrauterine system and endometrial surveillance at 6 months
B. Cyclical oral progestogen therapy for 6 months then repeat biopsy
C. Total hysterectomy with bilateral salpingo-oophorectomy
D. High-dose continuous oral progestogen therapy with repeat biopsy at 3-6 months (Correct Answer)
E. Endometrial ablation followed by assisted conception
Explanation: ***High-dose continuous oral progestogen therapy with repeat biopsy at 3-6 months***
- In a woman with **complex endometrial hyperplasia without atypia** who wishes to **preserve fertility**, high-dose **continuous oral progestogens** are the treatment of choice to induce regression.
- **Repeat endometrial biopsy at 3-6 months** is crucial to confirm regression and ensure no progression to atypical hyperplasia or carcinoma before attempting conception.
*Levonorgestrel intrauterine system and endometrial surveillance at 6 months*
- While the **LNG-IUS** is an effective treatment for endometrial hyperplasia, the patient's desire for **immediate conception** makes an indwelling device less suitable.
- For active management aiming for rapid regression and subsequent conception, a 3-6 month surveillance interval with oral therapy is often preferred over the 6-month interval mentioned.
*Cyclical oral progestogen therapy for 6 months then repeat biopsy*
- **Cyclical progestogens** are significantly less effective than **continuous progestogen therapy** for inducing regression of complex endometrial hyperplasia.
- The patient's risk factors of **obesity (BMI 36)** and **type 2 diabetes** contribute to unopposed estrogen, requiring continuous progestogen exposure for effective management.
*Total hysterectomy with bilateral salpingo-oophorectomy*
- **Hysterectomy** is a definitive treatment for endometrial hyperplasia but is contraindicated here as the patient specifically **wishes to preserve her fertility**.
- This surgery is typically reserved for cases with atypia, malignancy, or when fertility preservation is not desired.
*Endometrial ablation followed by assisted conception*
- **Endometrial ablation** destroys the uterine lining, making **future pregnancy impossible** or extremely high-risk due to inadequate endometrial support and potential complications.
- Ablation also prevents effective **endometrial surveillance** with biopsies, which is essential to monitor for persistence or progression of hyperplasia.
Question 34: A 30-year-old woman is found to have a right cornual ectopic pregnancy measuring 18 mm with a serum beta-hCG of 2,400 IU/L. She is haemodynamically stable with mild right lower quadrant pain. There is no haemoperitoneum on ultrasound. She has had two previous lower segment caesarean sections. What is the most appropriate initial management for this patient?
A. Expectant management with serial beta-hCG monitoring
B. Single-dose intramuscular methotrexate 50 mg/m²
C. Laparoscopic cornual resection (Correct Answer)
D. Laparotomy and cornual resection with hysterectomy
E. Ultrasound-guided potassium chloride injection into the gestational sac
Explanation: ***Laparoscopic cornual resection*** - **Cornual (interstitial) pregnancies** are high-risk due to their location within the **myometrium**, near major **uterine blood vessels**, posing a significant risk of rupture and severe hemorrhage. - Given the patient's stability, **laparoscopic cornual resection** is the preferred definitive surgical management to remove the ectopic tissue and prevent catastrophic rupture, especially since medical management often has lower success rates for cornual pregnancies.*Expectant management with serial beta-hCG monitoring* - This approach is unsuitable for cornual pregnancies due to their inherent **high risk of rupture** and potentially life-threatening hemorrhage, even if the patient is currently stable. - Expectant management is typically reserved for **low-risk, resolving tubal ectopics** with very low and declining beta-hCG levels.*Single-dose intramuscular methotrexate 50 mg/m²* - **Methotrexate** has a significantly **lower success rate** for cornual pregnancies compared to tubal ectopics because of the thick surrounding **myometrium** and rich vascularity, which limits drug penetration. - There is a persistent risk of **delayed rupture** with methotrexate, making surgical intervention a safer and more definitive option for cornual pregnancies.*Laparotomy and cornual resection with hysterectomy* - **Laparotomy** (open surgery) is usually reserved for **hemodynamically unstable** patients or cases of ruptured ectopic pregnancy with significant hemorrhage. This patient is currently stable, making laparoscopy more appropriate. - **Hysterectomy** is an extreme measure not indicated as initial management for a stable cornual ectopic; it's reserved for situations of **uncontrollable bleeding** or extensive uterine damage.*Ultrasound-guided potassium chloride injection into the gestational sac* - This local injection method is typically used for specific types of ectopic pregnancies, such as **cervical** or certain **abdominal pregnancies**, or in cases where systemic medical or surgical options are contraindicated. - For **cornual pregnancies**, **surgical resection** (laparoscopic) is generally considered the gold standard due to its higher success rates and ability to definitively remove the tissue and manage potential vascular complications.
Question 35: A 44-year-old woman presents with heavy menstrual bleeding lasting 8 days each cycle for the past 10 months. She has no intermenstrual or postcoital bleeding. Pelvic examination is normal and transvaginal ultrasound shows a uniformly enlarged uterus measuring 11 cm with heterogeneous myometrium and no focal lesions. Endometrial thickness is 9 mm in the secretory phase. Full blood count shows haemoglobin of 102 g/L. She has completed her family and desires definitive treatment. What is the most appropriate next step in management?
A. Hysteroscopy and endometrial biopsy
B. Levonorgestrel intrauterine system insertion (Correct Answer)
C. MRI pelvis to characterise myometrial pathology
D. Referral for endometrial ablation
E. Referral for hysterectomy
Explanation: ***Levonorgestrel intrauterine system insertion***
- The clinical presentation of **heavy menstrual bleeding** along with a **uniformly enlarged uterus** and **heterogeneous myometrium** on ultrasound strongly suggests **adenomyosis**.
- The **Levonorgestrel Intrauterine System (LNG-IUS)** is the recommended **first-line medical treatment** for heavy menstrual bleeding, including cases of adenomyosis, as it significantly reduces menstrual blood loss.
*Hysteroscopy and endometrial biopsy*
- **Endometrial sampling** is typically indicated for women **over 45 years** with heavy menstrual bleeding or those with **risk factors for malignancy**, such as intermenstrual bleeding or thickened endometrium.
- This patient is **44 years old** with no intermenstrual bleeding and a normal endometrial thickness (9 mm in secretory phase), making endometrial pathology less likely to be the primary cause.
*MRI pelvis to characterise myometrial pathology*
- While **MRI** is the **gold standard** for diagnosing adenomyosis, the ultrasound findings are already highly suggestive, and the initial management with LNG-IUS remains the same.
- MRI is usually reserved for cases where the diagnosis is uncertain, or for **surgical planning** if medical management fails and more invasive treatment is being considered.
*Referral for endometrial ablation*
- **Endometrial ablation** is often less effective in patients with **adenomyosis** because the ectopic endometrial tissue is located deep within the myometrium.
- It is also generally less successful or contraindicated in uteri larger than 10-12 cm, and medical management should be exhausted first.
*Referral for hysterectomy*
- Although the patient has completed her family and desires definitive treatment, current guidelines recommend attempting **medical management** first, such as the LNG-IUS.
- **Hysterectomy** is a major surgical intervention and is typically reserved for cases where medical treatments have failed, are contraindicated, or are declined by the patient after thorough discussion of alternatives.
Question 36: A 27-year-old woman presents to the emergency department with 6 weeks amenorrhoea and mild cramping lower abdominal pain. Transvaginal ultrasound shows an empty uterus with endometrial thickness of 12 mm and no adnexal masses. Serum beta-hCG is 950 IU/L. A repeat beta-hCG test 48 hours later shows a level of 1,280 IU/L. She is haemodynamically stable with mild tenderness in the right iliac fossa. What is the most appropriate classification of this clinical scenario?
A. Intrauterine pregnancy too early to visualise
B. Pregnancy of unknown location with suboptimal rise in beta-hCG (Correct Answer)
C. Ectopic pregnancy requiring immediate surgical intervention
D. Complete miscarriage with residual beta-hCG
E. Heterotopic pregnancy
Explanation: ***Pregnancy of unknown location with suboptimal rise in beta-hCG***
- A **Pregnancy of Unknown Location (PUL)** is defined when serum beta-hCG is positive but there is no evidence of an intrauterine or extrauterine pregnancy on **transvaginal ultrasound**.
- A rise of only 34.7% (from 950 to 1,280 IU/L) over 48 hours is considered a **suboptimal rise**, as a viable intrauterine pregnancy typically shows an increase of at least **53-66%**.
*Intrauterine pregnancy too early to visualise*
- While a pregnancy may be too small to see below the **discriminatory zone** (usually 1,500
–2,000 IU/L), the slow rate of rise makes a viable **intrauterine pregnancy (IUP)** less likely.
- Most viable IUPs would demonstrate a much more robust doubling or significant percentage increase in **beta-hCG** levels over 48 hours.
*Ectopic pregnancy requiring immediate surgical intervention*
- Surgical intervention is indicated for patients who are **haemodynamically unstable**, have signs of **peritonitis**, or have a large adnexal mass on scan.
- This patient is **stable** with a low beta-hCG and no adnexal mass, meaning expectant or medical management is often prioritized over **immediate surgery**.
*Complete miscarriage with residual beta-hCG*
- In a **complete miscarriage**, beta-hCG levels are expected to **resolve or decline** significantly (usually by >50%) rather than increase.
- The rising hCG trend in this case contradicts the diagnosis of a completed passing of products of conception.
*Heterotopic pregnancy*
- This refers to the rare simultaneous occurrence of an **intrauterine** and **extrauterine** pregnancy, often associated with **assisted reproductive technology (ART)**.
- There is no ultrasound evidence of an **intrauterine sac** or an extrauterine mass to support this complex diagnosis in this patient.
Question 37: A 40-year-old woman with von Willebrand disease type 1 presents with heavy menstrual bleeding that significantly impacts her quality of life. She reports flooding, passing large clots, and requiring time off work. Previous treatments with tranexamic acid and mefenamic acid provided insufficient improvement. She does not wish to have more children. Pelvic examination and ultrasound are normal. What is the most appropriate next management step?
A. Total hysterectomy
B. Levonorgestrel intrauterine system insertion (Correct Answer)
C. Combined oral contraceptive pill
D. Desmopressin (DDAVP) during menstruation
E. Endometrial ablation
Explanation: ***Levonorgestrel intrauterine system insertion***
- The **LNG-IUS** is highly effective for heavy menstrual bleeding in patients with **von Willebrand disease**, reducing blood loss by up to 97% through local **endometrial suppression**.
- It is particularly suitable for this patient as she has **normal pelvic anatomy**, does not wish to have more children, and has failed initial medical management with tranexamic and mefenamic acid.
*Total hysterectomy*
- This is a **definitive surgical treatment** but carries significant risks of **perioperative hemorrhage** in patients with baseline bleeding disorders, especially with vWD.
- It should only be considered after less invasive treatments have failed and requires meticulous coordination with a **hematologist** due to the underlying bleeding disorder.
*Combined oral contraceptive pill*
- While the **COCP** can increase factor VIII and vWF levels and reduce bleeding, it typically provides less **menstrual suppression** than the LNG-IUS for severe menorrhagia in vWD.
- It carries systemic risks such as **venous thromboembolism**, making local hormonal delivery often preferable if the patient is suitable for an IUD.
*Desmopressin (DDAVP) during menstruation*
- **DDAVP** works by releasing **vWF and Factor VIII** from endothelial stores, which is helpful in **Type 1 vWD**, but is often insufficient as a monotherapy for severe menorrhagia.
- Frequent use during menstruation can lead to **tachyphylaxis** and risks like **hyponatremia** due to its antidiuretic effect, limiting its long-term efficacy.
*Endometrial ablation*
- This procedure has a higher **failure rate** in women with systemic bleeding disorders like vWD compared to those with local pathology.
- It carries a risk of **uncontrolled intraoperative bleeding** and may lead to hematometra or difficult-to-monitor bleeding in the future due to the underlying coagulopathy.
Question 38: A 36-year-old woman with a history of pelvic inflammatory disease presents with 6 weeks amenorrhoea and minimal brown vaginal discharge. She has mild left iliac fossa discomfort but is haemodynamically stable. Transvaginal ultrasound shows an empty uterus and a 28 mm left adnexal mass with a hyperechoic ring. Free fluid is visible in the pouch of Douglas. Serum beta-hCG is 2200 IU/L. She has normal renal and liver function and agrees to medical management. What additional investigation should be performed before administering methotrexate?
A. Serum progesterone level
B. Full blood count including white cell differential (Correct Answer)
C. Pelvic MRI scan
D. Diagnostic laparoscopy to confirm diagnosis
E. Repeat beta-hCG in 48 hours to confirm trend
Explanation: ***Full blood count including white cell differential***
- **Methotrexate** is a **folate antagonist** and **cytotoxic agent** known to cause **bone marrow suppression**, which can lead to **leukopenia**, **neutropenia**, and **thrombocytopenia**. A baseline **Full Blood Count (FBC)** is essential to assess the patient's haematological status before starting treatment.
- Ensuring a normal **white cell differential** and **platelet count** is crucial to establish a baseline, identify any pre-existing haematological issues, and mitigate the risk of severe adverse effects or contraindications to **medical management**.
*Serum progesterone level*
- **Serum progesterone levels** are sometimes used to help differentiate between viable and non-viable pregnancies or **pregnancies of unknown location (PUL)**, but they do not guide the immediate decision for **methotrexate** administration in a diagnosed ectopic pregnancy.
- Given the strong evidence for **ectopic pregnancy** from the clinical picture, **beta-hCG level**, and **transvaginal ultrasound** (empty uterus, adnexal mass, free fluid), this test provides no additional utility for initiating treatment.
*Pelvic MRI scan*
- **Transvaginal ultrasound (TVUS)** is the **gold standard** for diagnosing and localizing **ectopic pregnancies**, and in this case, it has already provided sufficient diagnostic information with the identification of an **adnexal mass** and free fluid.
- A **pelvic MRI** scan is not a routine investigation for **ectopic pregnancy** and would unnecessarily delay the initiation of **medical management** without adding crucial information for treatment decisions.
*Diagnostic laparoscopy to confirm diagnosis*
- **Diagnostic laparoscopy** is an invasive surgical procedure with associated risks and is typically reserved for cases of **haemodynamic instability**, suspected rupture, or when the diagnosis remains uncertain despite non-invasive investigations.
- The patient is **haemodynamically stable** and meets the criteria for **medical management** of an **ectopic pregnancy**, making an invasive procedure like laparoscopy unnecessary at this stage.
*Repeat beta-hCG in 48 hours to confirm trend*
- While **serial beta-hCG measurements** are vital for monitoring **pregnancies of unknown location (PUL)** or assessing the effectiveness of **methotrexate treatment** post-administration, they are not a prerequisite for initiating treatment once an **ectopic pregnancy** is clearly diagnosed and medical management is indicated.
- Delaying **methotrexate** for 48 hours to confirm an hCG trend, especially with a confirmed **adnexal mass** on ultrasound, could potentially increase the risk of **tubal rupture** in a patient eligible for immediate treatment.
Question 39: A 48-year-old perimenopausal woman presents with a 13-month history of increasingly irregular and heavy menstrual bleeding. She experiences flooding with clots and cycles varying between 18-45 days. Pelvic examination is normal. Transvaginal ultrasound shows endometrial thickness of 14 mm and normal ovaries. What is the most important next investigation?
A. Serum FSH and LH levels
B. Endometrial sampling (Correct Answer)
C. MRI pelvis
D. Hysteroscopy and dilation and curettage
E. Coagulation screen
Explanation: ***Endometrial sampling***
- In women over **45 years** with irregular, heavy menstrual bleeding or an **endometrial thickness >10-12 mm**, tissue diagnosis is mandatory to rule out **endometrial hyperplasia or malignancy**.
- This patient is at high risk due to her **perimenopausal status** and potential for **unopposed estrogen** exposure during anovulatory cycles.
*Serum FSH and LH levels*
- While these levels can confirm the **perimenopausal transition**, they provide no information regarding the structural or pathological cause of the bleeding.
- Hormonal testing does not replace the need for tissue diagnosis to exclude **uterine cancer**.
*MRI pelvis*
- **Transvaginal ultrasound** has already provided sufficient imaging by identifying a thickened endometrium; MRI is not a first-line investigation for **abnormal uterine bleeding**.
- MRI is generally reserved for staging known malignancies or characterizing complex **myomas/adenomyosis**, not for initial endometrial assessment.
*Hysteroscopy and dilation and curettage*
- While this can provide a diagnosis, **outpatient endometrial sampling** (e.g., Pipelle) is the preferred, less invasive initial step before considering surgical intervention.
- **Hysteroscopy** is typically indicated if outpatient sampling is unsuccessful, providing inadequate samples, or if structural lesions like **polyps** are suspected.
*Coagulation screen*
- This is primarily indicated in younger women with heavy bleeding since menarche or those with a clinical history suggestive of **bleeding disorders**.
- Age-related pathology like **endometrial hyperplasia** is a much more critical and likely diagnosis to exclude in a 48-year-old before investigating systemic coagulation.
Question 40: A 43-year-old woman with heavy menstrual bleeding undergoes hysteroscopy which reveals a normal uterine cavity with no polyps or fibroids. Endometrial biopsy shows proliferative endometrium with no atypia. She has regular cycles every 28 days. Full blood count shows haemoglobin 102 g/L. She does not wish to use hormonal treatments. What is the most appropriate pharmacological management?
A. Tranexamic acid during menstruation only (Correct Answer)
B. Continuous combined hormone replacement therapy
C. Cyclical oral progestogens days 5-26 of cycle
D. Danazol
E. GnRH analogues
Explanation: ***Tranexamic acid during menstruation only***- **Tranexamic acid** is the first-line **non-hormonal** treatment for heavy menstrual bleeding, effectively reducing blood loss by 40-50% through its **antifibrinolytic** action.- It is ideal for this patient because it is only taken during the duration of menses and respects her preference to avoid **hormonal treatments**.*Continuous combined hormone replacement therapy*- This therapy is primarily indicated for **menopausal symptom relief** and is not appropriate for a 43-year-old with regular ovulatory cycles.- It contains hormones, which specifically contradicts the patient's expressed preference for **non-hormonal** management.*Cyclical oral progestogens days 5-26 of cycle*- This regimen is a **hormonal treatment** typically used for **anovulatory** heavy menstrual bleeding, whereas this patient has regular cycles and a proliferative endometrium suggesting normal ovulation.- The patient explicitly stated she does not wish to use **hormonal treatments**, making this an inappropriate choice.*Danazol*- **Danazol** is an androgenic steroid that is rarely used as first-line therapy due to significant side effects like **weight gain**, acne, and hirsutism.- It is a **hormonal** intervention, which falls outside the patient's request for non-hormonal options.*GnRH analogues*- These medications induce a state of **medical menopause** and are generally reserved as a short-term pre-operative measure for fibroids.- They carry a high risk of **bone mineral density loss** and vasomotor symptoms, and they represent a form of intensive **hormonal** manipulation.
